Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors (DEMFOS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04221750 |
Recruitment Status :
Recruiting
First Posted : January 9, 2020
Last Update Posted : February 3, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Frailty Sarcopenic Obesity Aging | Behavioral: Lifestyle therapy Drug: Metformin Hydrochloride Drug: Placebo Behavioral: Healthy Lifesylte | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 114 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Masking Description: | Placebo controlled |
Primary Purpose: | Treatment |
Official Title: | Lifestyle Intervention Plus Metformin to Treat Frailty in Older Veterans With Obesity |
Actual Study Start Date : | May 14, 2021 |
Estimated Primary Completion Date : | September 30, 2025 |
Estimated Study Completion Date : | September 30, 2026 |

Arm | Intervention/treatment |
---|---|
Experimental: Lifestyle Therapy plus Metformin
Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
|
Behavioral: Lifestyle therapy
Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
Other Name: Diet-induced weight loss and exercise training Drug: Metformin Hydrochloride Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily. |
Placebo Comparator: Lifestyle Therapy plus Placebo
Diet-induced weight loss and Exercise Training plus Placebo
|
Behavioral: Lifestyle therapy
Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced ~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
Other Name: Diet-induced weight loss and exercise training Drug: Placebo Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily. |
Active Comparator: Healthy lifestyle plus Metformin
Healthy lifestyle and Metformin 1 gm bid
|
Drug: Metformin Hydrochloride
Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily. Behavioral: Healthy Lifesylte Group educational sessions that focus on healthy diet, exercise, and social support once a month |
- Change in the modified Physical Performance Test (PPT) [ Time Frame: 6 months ]The Physical Performance Test includes seven standardized tasks (walking 15.2 m [50 ft], putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg test) plus two additional tasks (going up and down four flights of stairs and making a 360-degree turn). The score for each task ranges from 0 to 4, with higher scores indicating better physical performance; a perfect score would be 36.
- Change in muscle strength [ Time Frame: 6 months ]Assessed by biodex dynamometer and1-repetition maximum
- Change in dynamic balance [ Time Frame: 6 months ]Assessed by the obstacle course
- Change in static balance [ Time Frame: 6 months ]Assessed by one leg stance
- Change in gait speed [ Time Frame: 6 months ]Assessed by time need to walk 25 ft
- Change in peak aerobic power [ Time Frame: 6 months ]Assessed by indirect calorimetry during a graded exercise test
- Change in lean body mass [ Time Frame: 6 months ]Assessed by dual-energy x-ray absorptiometry (DXA)
- Chang in body fat [ Time Frame: 6 months ]Assessed by DXA
- Change in thigh muscle [ Time Frame: 6 months ]Assessed by magnetic resonance imaging (MRI)
- Change in thigh fat [ Time Frame: 6 months ]Assessed by MRI
- Change in muscle quality [ Time Frame: 6 months ]Assessed by ratio of skeletal strength per unit of skeletal muscle
- Change in bone microarchitecture [ Time Frame: 6 months ]Assessed by high-resolution peripheral quantitative computed tomograph (HR-pQCT)
- Change in bone strength [ Time Frame: 6 months ]Assessed by finite-element analyses
- Change in hip, lumbar spine, and wrist bone mineral density (BMD) [ Time Frame: 6 months ]Assessed by DXA
- Change in wrist and tibial cortical and trabecular BMD [ Time Frame: 6 months ]Assessed by HR-pQCT
- Change in serum C-telopeptide [ Time Frame: 6 months ]Assessed by immunoassay
- Change in subjective ability to function [ Time Frame: 6 months ]Assessed by Functional Status Questionnaire (score range: 0 to 36 with higher scores indicating better function)
- Change in telomere length in skeletal muscles and whole blood [ Time Frame: 6 months ]Assessed by Q-PCR
- Change in mood [ Time Frame: 6 months ]Assessed by geriatric depression scale (score range: 0 to 30, where lower scores indicating better mood)
- Change in serum osteocalcin [ Time Frame: 6 months ]Assessed by ELISA
- Changed in concentration of targeted metabolites [ Time Frame: 6 months ]Assessed by liquid chromatography hyphenated with mass spectrometry techniques
- Change in serum procollagen type 1 N propeptide [ Time Frame: 6 months ]Assessed by radioimmunoassay
- Change in serum sclerostin [ Time Frame: 6 months ]Assessed by ELISA
- Change in serum 25-OH vitamin D [ Time Frame: 6 months ]Assessed by immunoassay
- Change in serum parathyroid hormone [ Time Frame: 6 months ]Assessed by immunoassay
- Change in serum Interleukin 6 [ Time Frame: 6 months ]Assessed by immunoassay
- Change in Tumor necrosis factor [ Time Frame: 6 months ]Assessed by immunoassay
- Change in high-sensitivity c-reactive protein [ Time Frame: 6 months ]Assessed by immunoassay
- Change in p16 [ Time Frame: 6 months ]Assessed by immunohistochemistry
- Change in p21 [ Time Frame: 6 months ]Assessed by immmnohistochemistry
- Change in satellite cells [ Time Frame: 6 months ]Assessed by by immunofluorescence
- Change in fiber cross sectional area [ Time Frame: 6 months ]Assessed by immunohistochemistry
- Change in fiber type-specific response [ Time Frame: 6 months ]Assessed by immunofluorescence
- Change in gene expression of senescence associated secretory phenotype [ Time Frame: 6 months ]Assessed by RT-PCR
- Change in protein expression of senescence associated secretory phenotype [ Time Frame: 6 months ]Assessed by western blotting
- Change in Medical Outcomes 36-Item short form Health survey (SF-36) [ Time Frame: 6 months ]Assessed by Physical component summary and mental component summary score (score range 0 to 100, with higher scores indicating better health status)
- Change in Impact of Weight on Quality of Life_Lite (IWQOL-lite) score [ Time Frame: 6 months ]Assessed by IWQO-liteL questionnaire
- Change in serum adiponectin [ Time Frame: 6 months ]Assessed by ELISA
- Change in serum leptin [ Time Frame: 6 months ]Assessed by ELISA
- Change in fasting serum insulin [ Time Frame: 6 months ]Assessed by immunoassay
- Change in fasting serum glucose [ Time Frame: 6 months ]Assessed by glucose oxidase method
- Change in blood pressure [ Time Frame: 6 months ]Assessed by sphygmonanometry
- Change in serum lipids [ Time Frame: 6 months ]Assessed by automated enzymatic/colorimetric assays
- Change in insulin growth factor 1 [ Time Frame: 6 months ]Assessed by immunoassay
- Change in Cognitive composite scores [ Time Frame: 6 months ]
Using cognitive toolbox which yields the following summary scores: Cognitive Function
Composite Score, Fluid Cognition Composite Score, and Crystallized Cognition Composite Score (score range: -3 to +3 for each with higher scores indicating better cognitive status
- Change in habitual physical activity assessed by questionnaires [ Time Frame: 6 months ]Using the Stanford physical activity questionnaire (score range: 0 to 40 with higher scores indicating higher physical activity levels)
- Change in habitual physical activity measured objectively [ Time Frame: 6 months ]Using accelerometers

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 85 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- BMI = or > 30 kg/m2
- Stable body weight (plus/minus 2 kg) during the past 6 months
- Sedentary (regular exercise <1 h/wk or <2 x/wk for the last 6 months)
- Willing to provide informed consent
Exclusion Criteria:
- Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, or use of metformin, in which exercise, dietary restrictions, or metformin are contraindicated, or that would interfere with interpretation of results
- Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstable disease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonary disease requiring steroid pills or the use of supplemental oxygen) that would contraindicate exercise or dietary restriction
- Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, active rheumatoid arthritis) disease or impairments that would contraindicate participation in exercise
- Renal impairment as defined by an estimated glomerular filtration rate (eGFR of less than 30 mL/min/1.73 m2) in which metformin is contraindicated
- Other significant co-morbid disease that would impair ability to participate in the exercise intervention (e.g. severe psychiatric disorder [e.g. bipolar, schizophrenia], excess alcohol use [>14 drinks per week])
- Severe visual or hearing impairments that would interfere with following directions
- Significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State Exam (i.e. MMSE score <24)69
- Uncontrolled hypertension (BP>160/90 mm Hg)
- History of malignancy during the past 5 years (except non-melanoma skin cancers)
- Current use of bone acting drugs (e.g. use of estrogen, or androgen containing compound,raloxifene, calcitonin, parathyroid hormone during the past year or bisphosphonates during the last two years)
- Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragility fractures
-
Known history of diabetes mellitus or any of the following:
- fasting blood glucose of 126 mg/dl, 2-h blood glucose 200 mg/dl in the OGTT, or HbA1c of 6.5% or >
- Terminal illness with life expectancy less than 12 months, as determined by a physician
- Use of any drugs or natural products designed to induce weight loss within past three months
- History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men)
- Positive exercise stress test for ischemia or any indication for early termination of exercise stress testing
- Taking metformin or any other glucose lowering drug
- Lives outside of the study site or is planning to move out of the area in the next 2 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04221750
Contact: Dennis T Villareal, MD | (713) 794-7151 | Dennis.Villareal@va.gov | |
Contact: Arjun Paudyal, MS | (713) 578-4300 |
United States, Texas | |
Michael E. DeBakey VA Medical Center, Houston, TX | Recruiting |
Houston, Texas, United States, 77030-4211 | |
Contact: Dennis T Villareal, MD 713-794-7151 Dennis.Villareal@va.gov | |
Principal Investigator: Dennis T Villareal, MD |
Principal Investigator: | Dennis T Villareal, MD | Michael E. DeBakey VA Medical Center, Houston, TX |
Responsible Party: | VA Office of Research and Development |
ClinicalTrials.gov Identifier: | NCT04221750 |
Other Study ID Numbers: |
ENDA-007-19F H-46970 ( Other Grant/Funding Number: VA Office of Research and Development ) |
First Posted: | January 9, 2020 Key Record Dates |
Last Update Posted: | February 3, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication (guidance is provided on the ORD website). MEDVAMC will not provide unrestricted, open public access to large scale health related datasets because of re-identification concerns and the obligation to protect Veterans' private information. However, controlled public access will be provided to the greatest extent possible under specific DUAs or other written agreements, and open access will be provided to the final datasets underlying peer-reviewed publications (aggregated data that can be released with privacy and confidentiality risks). |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Obesity Frailty Overweight Overnutrition Nutrition Disorders |
Body Weight Pathologic Processes Metformin Hypoglycemic Agents Physiological Effects of Drugs |